Related Experiment Video
Updated: Apr 14, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Neuropeptide Y Promoter Variant rs16147 (-399 T/C) Is Associated With Susceptibility to Polycystic Ovary Syndrome
Fulya Yukcu1, Raziye Akcilar2, Ismail Biyik3
1Department of Biophysics, Faculty of Medicine, Kutahya Health Sciences University, Kutahya, TUR.
Abstract:
Background Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder with complex genetic and neuroendocrine underpinnings. Neuropeptide Y (NPY), a key regulator of energy balance and reproductive function, has been implicated in hypothalamic-pituitary-ovarian (HPO) axis dysregulation. However, data on variants of the NPY gene in PCOS remain limited. This study investigated the association between the NPY promoter variant rs16147 (-399 T/C) and susceptibility to PCOS. Methods In this case-control study, 102 women diagnosed with PCOS according to the Rotterdam criteria and 102 age-matched healthy controls were enrolled. Genomic DNA was extracted from peripheral blood samples, and genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Demographic and anthropometric characteristics were recorded, and hormonal and metabolic parameters, including luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), total testosterone, fasting glucose, insulin levels, lipid profile components, and homeostasis model assessment of insulin resistance (HOMA-IR), were evaluated. Genotype-phenotype associations were also explored. Results Genotype and allele distributions differed significantly between groups. The CT genotype was detected in 84 women with PCOS (82.4%) compared to 24 controls (23.5%) and was associated with increased susceptibility to PCOS (odds ratio {OR} = 15.1; 95% confidence interval {CI}: 7.65-30.0; p < 0.001). In contrast, the CC genotype was more frequent in controls (78, 76.5%) than in the PCOS group (18, 17.6%). The TT genotype was not observed in either group. Similarly, the T allele was more prevalent in women with PCOS (84, 41.2%) than in controls (24, 11.8%) (OR = 5.25; 95% CI: 3.15-8.73; p < 0.001). No significant associations were observed between rs16147 genotypes and hormonal or metabolic parameters within the PCOS cohort. Conclusions The NPY promoter variant rs16147, particularly the CT genotype and T allele, may contribute to genetic susceptibility to PCOS rather than to clinical phenotype severity. However, these findings should be interpreted with caution and require validation in larger, multicenter populations.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Principles of Pharmacogenetics: Types of Genetic Variants

